gip/glp 1-agonist tirzepatide GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Pharmacogenomics of Tirzepatide: Genomic Insights

Nystrm T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrn B, Sjholm A: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

1 g kg 1 d-allulose to suppress food intake was not significantly altered at 0.5 h, but the suppression of food intake was mildly attenuated at 1 h and blunted at 2, 3, and 6 h (Fig

[PubMed] [Google Scholar] 9.Frias JP, Bonora E, Nevarez Ruiz L, et al

Sequences of receptor clones were confirmed by DNA sequencing

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity (2020)

Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications